Evidence map›Paper›PMID 31431694›Full record

ReviewBone marrow transplantation2019

Transplantation tolerance in nonhuman primates and humans.

Megan Sykes, Adam D Griesemer

Open access · greenAbstract readReview
In one paragraph

Review in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Expansion of CD45RAClinical & translational immunology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Megan SykesColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA. megan.sykes@columbia.edu.
Adam D GriesemerColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Columbia University Irving Medical Center · US

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
Transcriptomics and Repertoire ProfilingP01AI106697 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Peter Alan Sims · 2013 to 2026
$31.3M
Using Polyclonal Tregs to Develop a Compressed BMT Regiment for Deceased Donor Islets and KidneysU19AI131474 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SYKES, MEGAN · 2017 to 2022
$12.1M
STATISTICAL COREP01CA111519 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PREFFER, FREDERIC IRA · 2006 to 2010
$9.3M
Robust allograft tolerance in non-human primatesR01OD017949 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SYKES, MEGAN · 2015 to 2019
$4.5M
Mechanisms of tolerance in recipients of combined kidney and bone marrow transplaR01AI084074 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SYKES, MEGAN · 2009 to 2010
$862k
Immune response to combined liver and bone marrow transplant for tolerance in NHPR56AI122332 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SYKES, MEGAN · 2016 to 2016
$320k
IMMUNE TOLERANCE NETWORK-266015416-266015416N01AI015416 · NIAID · REGENTS OF THE UNIVERSITY OF C · PI BLUESTONE, JEFFREY A · 2002 to 2006
–
NCI NIH HHS P01 CA111519NIAID NIH HHS N01 AI015416NIAID NIH HHS P01 AI106697NIAID NIH HHS R01 AI084074NIAID NIH HHS R56 AI122332NIAID NIH HHS U19 AI131474NIAID NIH HHS UM1 AI109565NIH HHS R01 OD017949
6 · The paper itself

Abstract

This review focuses on our recent studies involving nonmyeloablative bone marrow transplantation as an approach to inducing organ allograft tolerance across MHC barriers in nonhuman primates and in patients. The clinical studies are focused on mechanisms of tolerance involved in a protocol carried out at Massachusetts General Hospital in HLA-mismatched haploidentical combinations for the induction of renal allograft tolerance. These studies, in which chimerism was only transient and GVHD did not occur, suggest an early role for donor-specific regulatory T cells in tolerance induction, followed by partial and gradual deletion of donor-reactive T cells. We utilized high-throughput sequencing methodologies in a novel way to identify and track large numbers of alloreactive T cell receptors (TCRs). This method has been shown to identify biologically significant alloreactive TCRs in transplant patients and pointed to clonal deletion as a major mechanism of long-term tolerance in these patients. More recently, we adapted this sequencing method to optimally identify the donor-specific regulatory T cell (Treg) repertoire. Interrogation of the early posttransplant repertoire demonstrated expansion of donor-specific Tregs in association with tolerance. Our studies suggest a role for the kidney graft in tolerance by these mechanisms in patients who had only transient chimerism. Nonhuman primate studies indicate that other organs, including the heart, the lungs and the liver, are less readily tolerated following a period of transient mixed chimerism. Our efforts to extend the reach of mixed chimerism for tolerance induction beyond the kidney are therefore focused on the addition of recipient Tregs to the protocol. This approach has the potential to enhance chimerism while further reducing the risk of GVHD.

Indexed as

AnimalsHumansPrimatesTransplantation Tolerance

Identifiers

PMID31431694
PMCPMC7323053
OpenAlexW2969376730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.